Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The status of 10 targeted genes was evaluated by next‐generation sequencing (NGS) in 884 non‐small cell lung cancer (NSCLC) patients. The relationship between gene alterations and clinicopathological characters was analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Overall, 684 (77.4%) patients harbored gene alterations, and <i>EGFR </i> (510, 57.7%) was found to be the most common type of mutation followed by <i>KRAS </i> (91, 10.3%), <i>HER2 </i> (38, 4.3%), <i>PIK3CA </i> (32, 3.6%), <i>ALK </i> (21, 2.4%), <i>BRAF </i> (10, 1.1%), <i>ROS1 </i> (5, 0.6%), <i>RET </i> (5, 0.6%), <i>MET </i> (4, 0.5%) and <i>NRAS </i> (1, 0.1%) Gene alterations were more frequent in females, non‐smokers and adenocarcinoma (<i>P </i> < 0.001). <i>EGFR </i> mutations were associated with women, non‐smokers, normal level of serum tumor markers, and adenocarcinoma <i>(P </i> < 0.001). Patients without lymph node metastasis (<i>P </i> = 0.012), or early stage disease (<i>P </i> < 0.001) exhibited a higher <i>EGFR </i> mutation rate. <i>KRAS </i> mutations tended to arise in men (<i>P </i> < 0.001), smokers (<i>P </i> < 0.001) and patients with higher levels of serum tumor markers (<i>P </i> = 0.048). A mucus‐producing component was associated with <i>KRAS </i> (<i>P </i> < 0.001), <i>ROS1 </i> (<i>P </i> = 0.033) and <i>ALK </i> (<i>P </i> < 0.001) alterations. <i>ALK </i> and <i>ROS1 </i> rearrangements were more frequent in micropapillary structures (<i>P </i> = 0.004, <i>P </i> = 0.012). <i>BRAF </i> mutation was associated with advanced disease patients and micropapillary structure (<i>P </i> < 0.001). <i>PIK3CA </i> mutation was more likely to be found in elderly patients (<i>P </i> = 0.014). Some patients had synchronous gene alterations, including <i>EGFR/PIK3CA </i>, <i>EGFR/HER2 </i>, <i>HER2/KRAS </i>, <i>EGFR/KRAS </i>, <i>EGFR/ROS1 </i>, <i>EGFR/NRAS </i>, <i>KRAS/PIK3CA </i>, <i>KRAS/PIK3CA/HER2. </i></p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration had unique clinicopathological characteristics.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study revealed the frequency and distribution of 10 targeted gene abnormalities and their association with clinicopathological parameters of Chinese non‐small cell lung cancer (NSCLC) patients in eastern China.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>Some rare synchronous mutations were detected in our study by next‐generation sequencing (NGS).</p></section>

Specific Deletions of Chromosomes 3p, 5q, 13q, and 21q among Patients with G2 Grade of Non-Small Cell Lung Cancer

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer

Recurrent Chromosomal Imbalances in Nonsmall Cell Lung Carcinoma

Abstract 1945: Identification of a miRNA/mRNA network driving non-small cell lung cancer (NSCLC) dissemination

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Identification Of A Mirna/Mrna Network Driving Non-Small Cell Lung Cancer (Nsclc) Dissemination

Integrated Molecular Portrait of Non-Small Cell Lung Cancers.

Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer

Data from Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis

Research of Loss of Heterozygaity on Chromosome 3p in Non-Small Cell Lung Cancer

1P19q Codeletion and RET Rearrangements in Small Cell Lung Cancer.

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA)

Identification Of Novel Biomarkers And Candidate Small Molecule Drugs In Non-Small-Cell Lung Cancer By Integrated Microarray Analysis

The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients

Prevalence of Targeted Therapy-Related Genetic Variations in NSCLC and Their Relationship with Clinicopathological Characteristics

Abstract 2410: Comparative genomic profiling of unresectable NSCLC patients in the U.S. and China using a globally harmonized liquid biopsy assay platform

Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution